Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi
2006
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
2009 Standout
British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE
2013 Standout
Emerging azole antifungals
2005
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
2007
Vulvovaginal candidosis
2007 Standout
Practice Guidelines for the Treatment of Candidiasis
2000
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Natural products: A continuing source of novel drug leads
2013 Standout
New and emerging treatments for fungal infections
2007
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program
2005
Triazole‐Polyene Antagonism in Experimental Invasive Pulmonary Aspergillosis: In Vitro and In Vivo Correlation
2006
Prevalence of Vaginal Colonization by Drug‐ResistantCandidaSpecies in College‐Age Women with Previous Exposure to Over‐the‐Counter Azole Antifungals
2001
Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis
2003
Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes
2007 Standout
Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases
2004
Posaconazole: clinical pharmacology and potential for management of fungal infections
2005
Methods for in vitro evaluating antimicrobial activity: A review
2015 Standout
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
2005 Standout
Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
2006 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Newer Systemic Antifungal Agents
2004
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Echinocandin antifungal drugs
2003 Standout
Infections due to emerging and uncommon medically important fungal pathogens
2004
Posaconazole: a broad-spectrum triazole antifungal
2005
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints
2009
Zygomycosis (mucormycosis): emerging clinical importance and new treatments
2004
Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations
2006
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
2016 Standout
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis
2002
A Randomized Double‐Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis
2001
Comparison of an Aspergillus Real-time Polymerase Chain Reaction Assay With Galactomannan Testing of Bronchoalvelolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis in Lung Transplant Recipients
2011
Advances and challenges in management of invasive mycoses
2005
Co-infections in people with COVID-19: a systematic review and meta-analysis
2020 Standout
Posaconazole as Salvage Therapy in Patients with Chronic Granulomatous Disease and Invasive Filamentous Fungal Infection
2005
Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations
2011
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
2002 Standout
Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin
2007
Issues Related to the Design and Interpretation of Clinical Trials of Salvage Therapy for Invasive Mold Infection
2006
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
2007 Standout
In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium Species
2008
Antifungal drug resistance
1995
Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network
2009
Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis
2001
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Candida Infections of Medical Devices
2004 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
2009
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
2013 Standout
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Laboratory diagnosis of invasive aspergillosis
2005
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
AspergillusGalactomannan Enzyme Immunoassay and Quantitative PCR for Diagnosis of Invasive Aspergillosis with Bronchoalveolar Lavage Fluid
2004
2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa
2015 Standout
Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B
2004
Posaconazole: A Next-Generation Triazole Antifungal
2007
In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis
2003
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Fluconazole Prophylaxis in Extremely Low Birth Weight Neonates Reduces Invasive Candidiasis Mortality Rates Without Emergence of Fluconazole-Resistant Candida Species
2008
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
2006 Standout
Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyondCandida albicansandAspergillus fumigatus
2004
Anidulafungin
2005
Antifungal susceptibility testing inAspergillusspp. according to EUCAST methodology
2006
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients
2001
Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
2002
Efficacy of PLD-118, a Novel Inhibitor of Candida Isoleucyl-tRNA Synthetase, against Experimental Oropharyngeal and Esophageal Candidiasis Caused by Fluconazole-Resistant C. albicans
2004
Guidelines for Treatment of Candidiasis
2004 Standout
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
2001
Fungicidal Activity of Fluconazole against Candida albicans in a Synthetic Vagina-Simulative Medium
2003
Works of Joanne Peter being referenced
Experimental Pulmonary Aspergillosis Due toAspergillus terreus:Pathogenesis and Treatment of an Emerging Fungal Pathogen Resistant to Amphotericin B
2003
Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics
1999
Emergence of Resistance of Candida albicans to Clotrimazole in Human Immunodeficiency Virus-Infected Children: In Vitro and Clinical Correlations
2000
Transmission of an Azole-Resistant Isogenic Strain of Candida albicans among Human Immunodeficiency Virus-Infected Family Members with Oropharyngeal Candidiasis
1999
Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits
2004
Mechanisms of phagocytic host defense against Pseudallescheria boydii (Scedosporium apiospermum): an emerging polyene-resistant fungal pathogen in immunocompromised hosts
2002
Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis
2000